The liver X receptor alpha (LXRα) is a member of the nuclear hormone receptor superfamily that plays an important role in lipid homeostasis. Recent studies have demonstrated the importance of LXR signaling pathways in the development of metabolic disorders such as hyperlipidemia and atherosclerosis. Here we characterize two alternative human LXRα transcripts, designated LXRα2 and LXRα3. All three human LXRα isoforms are derived from the same gene via alternative splicing and differential promoter usage. The LXRα2 isoform lacks the first 45 amino acids of LXRα1. It is generated by through use of a novel promoter and first exon (designated 1c), which is nearly 10 kb upstream of the original exon 1a. LXRα3 lacks 50 amino acids within the ligand-binding domain and is generated through alternative recognition of the 3'-splice site in exon 6. LXRα2 and LXRα3 are expressed at lower levels compared with LXRα1 in most tissues, except that LXRα2 expression is dominant in testis. Both LXRα2 and LXRα3 heterodimerize with RXR and bind to LXR response elements. LXRα2 shows reduced transcriptional activity relative to LXRα1, indicating that the N-terminal domain of LXRα is essential for its full transcriptional activity.
INTRODUCTION
Nuclear hormone receptors are transcription factors that are involved in numerous biological processes, including reproduction, development, and metabolism (1) . Most of these receptors are comprised of a ligand-independent transcriptional activation function (AF-1) domain at the amino terminus, a DNA binding domain (DBD), a hinge region and a ligand-binding domain (LBD). The LBD possesses a dimerization interface, and a ligand-dependent activation function region (AF-2) at the carboxyl terminus (2) . The transcriptional activity of most nuclear hormone receptors is stimulated by specific small molecule ligands. Binding of ligand to the LBD results in a conformational change of the receptor, release of corepressors, recruitment of co-activators and transcriptional activation (3, 4) .
The Liver X receptors (LXRs) are nuclear hormone receptors that play a key role in the regulation of lipoprotein metabolism (5, 6) . LXRs are activated by oxidized derivatives of cholesterol that serve as ligands (7) (8) (9) . Two different LXRs have been described, LXRα (NR1H3) and LXRβ (NR1H2). LXRα is expressed at high levels in liver, adipose tissue, macrophages, intestine, kidney and spleen, whereas LXRβ is expressed ubiquitously (9) . Both LXRs heterodimerize with RXR and stimulate transcription through binding to DR-4 response elements (LXREs) in target gene promoters (10) .
To date, more than a dozen LXRs target genes have been identified. They are involved in hepatic bile acid and fatty acid synthesis, glucose metabolism, and sterol efflux (11) (12) (13) (14) (15) (16) . In the liver, LXRs regulate gene expression of CYP7A (17) and sterol regulatory binding element protein 1c (SREBP-1c) (18) , which are involved in cholesterol and fatty acid metabolism. In macrophages and other peripheral cell types, LXRs control the transcription of several genes involved in cellular cholesterol efflux including ATP-binding cassette ABCA1 (19, 20) , ABCG1 (21) , and apolipoprotein E (14) . LXRs also influence lipoprotein metabolism through the control of modifying enzymes such as lipoprotein lipase (22) , cholesteryl ester transfer protein (11) , and phospholipid transfer protein (13) . Ligands for LXR have been shown to inhibit by on February 6, 2008 www.jlr.org Downloaded from intestinal cholesterol absorption, promote hepatic sterol excretion and reduce atherosclerosis in murine models (18, (23) (24) (25) .
Multiple isoforms have been identified for many members of the nuclear hormone receptor family. In several cases, different receptor isoforms have been found to have distinct activities and to play distinct biological roles (2, 26) . Here we describe the identification characterization of two isoforms of human LXRα that have distinct expression patterns and altered transcriptional activity.
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EXPERIMENTAL PROCEDURES
Reagents and Plasmids
GW3965 and T0901317 were provided by T. Willson and J. Collins at GlaxoSmithKline. Ligands were dissolved in DMSO prior to use in cell culture. The full-length coding regions of human LXR isoforms were amplified by PCR using specific primers and subcloned into BamHI/XhoI sites of the mammalian expression vector pCMX-PL1, to create pCMX-LXRα1,pCMX-LXRα2, and pCMX-LXRα3 respectively.
Three isoforms of human LXRα were also subcloned into pEGFP-C1 vector using XhoI/BamHI sites to allow expression of N-terminal GFP-hLXRα fusion proteins. For retroviral expression constructs, inserts were excised from the pEGFP vectors using BglII/XhoI restriction enzymes and subcloned into BamHI/SalI sites of the pBabe vector to generate pBABE-GFP, pBABE-GFP-LXRα1, -LXRα2, and -LXRα3. The isoforms were also cloned into pShuttle-1 vector, which includes three repeats of FLAG tag in the N-terminus. The dominant negative (ΔAF2) of human LXRα was generated by cloning of amino acids 1-435 of hLXRα1 to pCMV-Tag3C (Stratagene) vector via BamHI /XhoI sites. All plasmids were confirmed by DNA sequencing.
Cell Culture, Transfection and Reporter Gene Assays
HepG2 and HEK-293 cells were cultured in modified Eagle's medium containing 10% fetal bovine serum or lipoprotein-deficient fetal bovine serum (LPDS). Transient transfections were performed in triplicate in 48-well plates. Cells were transfected with reporter plasmid (100 ng/well), receptor plasmids (5-50 ng/well), pCMV-β-galactosidase (50 ng/well), and pTKCIII (to a total of 205 ng/well) using the Lipofactamine 2000 reagent (Invitrogen). Following transfection, cells were incubated in modified Eagle's medium containing 10% LPDS and the indicated ligands or vehicle control for 24 h, and the results (mean ± S.E.; three experiments) were determined. Luciferase activities were assayed and normalized to beta-galactosidase activity.
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Quantitative PCR
Real-time quantitative PCR assays were performed by using an Applied Biosystems 7700 sequence detector. Total RNA was reverse-transcribed with random hexamers by using TaqMan reverse-transcription reagents (Applied Biosystems) according to the manufacturer's protocol. Real-time PCR Sybergreen green assays for LXRα transcript levels were performed essentially as described (15) . Samples were analyzed simultaneously for 36B4 expression. Quantitative expression values were extrapolated from separate standard curves. Each sample was assayed in duplicate and 
Gel Shift Assays
Human LXRα isoforms and human RXR were synthesized in vitro using the TNT T7-coupled reticulocyte system (Promega). To compare transcription/translation efficiency of the expression constructs expressing different human LXR isoforms, equal volumes of 35S-labeled lysates were loaded and separated on an 8% SDS-polyacrylamide gel. Gel shift assays were performed as described (15) using in vitro translated proteins.
Binding reactions were carried out in a buffer containing 10 mM HEPES, pH 7.8, 100 mM KCl, 0.2% Nonidet P-40, 6% glycerol, 0.3 mg/ml bovine serum albumin, 1 mM dithiothreitol, 2 µg of poly(dI-dC), 1-3 µl each of in vitro translated receptors and 32P end-labeled oligonucleotide. DNA-protein complexes were resolved on a 5% polyacrylamide gel. The sequence of the rat FAS LXRE oligonucleotide was (only one strand shown): 5'-gatcacgatgaccggtagtaaccccgcc-3'.
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Cells were transfected with retroviral vectors pBABE-GFP, pBABE-GFPLXRα1, pBABE-GFPLXRα2, and pBABE-GFPLXRα3, and selected with puromycin to generate stable cell lines. The cells were seeded in 4-well chamber slides and fixed in 4% paraformaldehyde for 10 mintues at room temperature. Slides were mounted in Vectashield medium for fluorescence with DAPI (Vector) analyzed under a Zeiss fluorescence microscope.
Western blot analysis
Cells transiently or stably transfected with FLAG-LXRα constructs were lysed in RIPA buffer. Supernatants were collected, and protein content was assayed using the Bio-Rad protein reagent. Samples containing equal amounts of protein were boiled in 250 mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 2% -mercaptoethanol, and then size separated in 8% SDS-PAGE. Proteins were transferred to nitrocellulose membrane.
Protein expression was detected with HRP-Anti-Flag antibody (M2) from Sigma, and visualized by the enhanced chemoluminescence (ECL) technique. 
RESULTS
By searching the expressed sequence tag (EST) database we identified two cDNA clones similar to human LXRα (BC041172, and BC008819). Primers based on the EST sequences were used to amplify these LXRα transcripts from cDNA and the products were subcloned and sequenced. Comparison of these sequences to the publicly available genomic sequence of human chromosome 11 (www.genome.ucsc.edu) revealed that these two new LXRα transcripts were generated by alternative RNA splicing. Since exons 1a and 1b are non-coding, the choice of these exons does not impact protein sequence. By contrast, translation of the LXRα2 mRNA starts in exon 3, leading to a truncated protein lacking the N-terminal 45 amino acids of LXRα1. The LXRα3 mRNA is generated by the removal of exon 6 through alternative splicing leading to an in-frame deletion of 50 amino acids from the LBD.
To determine the absolute level of expression of LXRα isoforms in different tissues, total RNA from 20 human tissues was reverse transcribed and real time quantitative PCR was performed. As shown in Figure 2A , the various LXRα isoforms differ in their patterns of expression. In normal tissues, the highest hLXRα1 expression was detected in liver, heart, brain, spleen, and kidney. LXRα2 was highly expressed in testis where it was the predominant isoform. LXRα3 was expressed at relatively lower levels in lung, thyroid gland, and spleen. In addition to normal tissues, transformed cell by on February 6, 2008 www.jlr.org Downloaded from lines representing lymphoma, melanoma, osteosarcoma, meduloblastoma, and glioma were analyzed ( Figure 2B ). Interestingly, the alternative isoforms α2 and α3 were somewhat more highly expressed in tumor cells compared to normal tissues.
Furthermore, the cell-type specific nature of alternative transcript expression was also evident from these samples.
To investigate if the alternative LXRα2 and α3 proteins were competent to bind DNA, they were produced in vitro using reticulocyte lysates. In vitro transcription/translation experiments confirmed the production of LXRα1, LXRα2, and LXRα3 proteins with expected molecular weights ( Figure 3A ). Electromobility shift assays (EMSA) revealed that both LXRα2 and LXRα3 retain the ability to heterodimerize with RXR and to bind the LXR response element (LXRE) from the fatty acid synthase (FAS gene) (12) ( Figure 3B ). To address the transcriptional activity of the LXRα2 and LXRα3 isoforms, we performed transient transfections in to HEK-293 cells.
As expected, transfection of an LXRα1 cDNA expression vector stimulated activity of an LXRE-driven luciferase reporter in a ligand (T1317, 1 µM) dependent manner ( Figure   3C ). Note, a low level of basal activity was observed with the LXRE reporter in the absence of transfected LXR due to the expression of endogenous LXRβ in HEK-293 cells. Transfection of an expression vector encoding the LXRα2 cDNA also promoted LXRE reporter expression, but it was clearly less active than LXRα1. By contrast, expression of LXRα3 cDNA did not stimulate reporter expression above basal levels. As a result of deletion of the 50 amino acids encoded by exon 6, the LXRα3 protein lacks helix 3, 4 and part of helix 5 that comprise the ligand-binding pocket of LXRα1 (27) . To ensure that the GFP fusion itself was not influencing the activity of the various LXR isoforms, we also explored the function of LXRα2 and LXRα3 using FLAG-tagged LXR fusion proteins. Transfection of these expression vectors into 293 cells produced equivalent levels of LXRα protein as determined by western blotting using an anti-FLAG antibody ( Figure 6A ). Consistent with the results presented above, FLAG-LXRα2 showed reduced activity compared to FLAG-LXRα1, while FLAG-LXRα3 was inactive ( Figure 6B ). Furthermore, a FLAG-tagged receptor containing two repeats of the Nterminal 74 amino acids showed increased activity compared to the wild type LXRα1 ( Figure 6B) . Finally, the isolated AF1 domain enhanced the transcription of a GAL4-luciferase reporter when it was fused with GAL4 DNA binding domain ( Figure 6C ). The three LXRα isoforms are differentially expressed in various human tissues.
hLXRα2 is expressed at lower levels compared with hLXRα1 in many tissues, including liver, heart, kidney, and brain etc. In testis, however, hLXRα2 is the predominant by on February 6, 2008 www.jlr.org
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isoform. The expression of the exon 1c transcript of hLXRα2 in a tissue-specific manner may reflect a requirement for tissue-or cell-specific protein factors to mediate expression from this promoter. hLXRα3 is expressed at a low level in most human tissues but at higher levels in tumor cells. Thus, the alternative splicing that generates hLXRα3 appears to occur with higher frequency in tumor cells. The significance of this observation remains to be explored. The possibility remains that LXRα2 and LXRα3 may be expressed at higher levels in cell types not examined here or may be induced in response to specific stimuli or metabolic conditions. Interestingly, the tissue-specific expression of LXRα isofroms is very similar to expression of analogous isoforms of its heterodimeric partner RXRα. Isoforms of RXRα also differ in their N-terminal region (28) . The major isoform, RXRα1, is widely expressed in embryos and adults, whereas RXRα2 and α3 are restricted to the adult testis (35) .
We also characterized the function of these two novel isoforms of LXRα. Both 
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